These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 14766884)

  • 41. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole.
    Espinel-Ingroff A; Barchiesi F; Cuenca-Estrella M; Pfaller MA; Rinaldi M; Rodriguez-Tudela JL; Verweij PE
    J Clin Microbiol; 2005 Aug; 43(8):3884-9. PubMed ID: 16081926
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of 24-hour and 48-hour voriconazole MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27-A3 document) in three laboratories: results obtained with 2,162 clinical isolates of Candida spp. and other yeasts.
    Espinel-Ingroff A; Canton E; Peman J; Rinaldi MG; Fothergill AW
    J Clin Microbiol; 2009 Sep; 47(9):2766-71. PubMed ID: 19571029
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro activity of fluconazole and voriconazole against clinical isolates of Candida spp. by E-test method.
    Madhavan P; Jamal F; Chong PP; Ng KP
    Trop Biomed; 2010 Aug; 27(2):200-7. PubMed ID: 20962716
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion.
    Hazen KC; Baron EJ; Colombo AL; Girmenia C; Sanchez-Sousa A; del Palacio A; de Bedout C; Gibbs DL;
    J Clin Microbiol; 2003 Dec; 41(12):5623-32. PubMed ID: 14662952
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro activities of voriconazole as a triazole derivative and caspofungin as an echinocandin were compared with those of some antifungal agents against Candida species isolated from clinical specimens.
    Ozçelik B; Kaynak F; Cesur S; Sipahi B; Sultan N
    Jpn J Infect Dis; 2007 Sep; 60(5):302-4. PubMed ID: 17881873
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Evaluation of the VITEK 2 system (AST-YSO1 cards) for antifungal susceptibility testing against different Candida species].
    Ochiuzzi ME; Arechavala A; Guelfand L; Maldonado I; Soloaga R;
    Rev Argent Microbiol; 2014; 46(2):111-8. PubMed ID: 25011594
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.
    Marco F; Pfaller MA; Messer S; Jones RN
    Antimicrob Agents Chemother; 1998 Jan; 42(1):161-3. PubMed ID: 9449278
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria.
    Pfaller MA; Andes D; Arendrup MC; Diekema DJ; Espinel-Ingroff A; Alexander BD; Brown SD; Chaturvedi V; Fowler CL; Ghannoum MA; Johnson EM; Knapp CC; Motyl MR; Ostrosky-Zeichner L; Walsh TJ
    Diagn Microbiol Infect Dis; 2011 Jul; 70(3):330-43. PubMed ID: 21546199
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antifungal effect of voriconazole on intracellular Candida glabrata, Candida krusei and Candida parapsilosis in human monocyte-derived macrophages.
    Bopp LH; Baltch AL; Ritz WJ; Michelsen PB; Smith RP
    J Med Microbiol; 2006 Jul; 55(Pt 7):865-870. PubMed ID: 16772413
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of the BIOMIC Video System to evaluate the susceptibility of clinical yeast isolates to fluconazole and voriconazole by a disk diffusion method.
    Dóczi I; Mestyán G; Puskás E; Nikolova R; Barcs I; Nagy E
    Acta Microbiol Immunol Hung; 2006 Jun; 53(2):135-44. PubMed ID: 16956125
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Potential fungicidal effect of voriconazole against Candida spp.
    Rubio MC; de Ocáriz IR; Gil J; Benito R; Rezusta A
    Int J Antimicrob Agents; 2005 Mar; 25(3):264-7. PubMed ID: 15737524
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of a new commercial colorimetric microdilution method with a standard method for in-vitro susceptibility testing of Candida spp. and Cryptococcus neoformans.
    Davey KG; Szekely A; Johnson EM; Warnock DW
    J Antimicrob Chemother; 1998 Oct; 42(4):439-44. PubMed ID: 9818741
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood.
    Maxwell MJ; Messer SA; Hollis RJ; Boyken L; Tendolkar S; Diekema DJ; Pfaller MA
    J Clin Microbiol; 2003 Mar; 41(3):1087-90. PubMed ID: 12624034
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of the Sensititre YeastOne colorimetric antifungal panel with a modified NCCLS M38-A method to determine the activity of voriconazole against clinical isolates of Aspergillus spp.
    Castro C; Serrano MC; Flores B; Espinel-Ingroff A; Martín-Mazuelos E
    J Clin Microbiol; 2004 Sep; 42(9):4358-60. PubMed ID: 15365044
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Voriconazole inhibits biofilm formation in different species of the genus Candida.
    Valentín A; Cantón E; Pemán J; Martínez JP
    J Antimicrob Chemother; 2012 Oct; 67(10):2418-23. PubMed ID: 22733651
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Altered susceptibility of Candida glabrata bloodstream isolates to triazoles at clinically relevant pH values: comparison of the NCCLS M27-A2, Sensititre YeastOne, and Etest methods.
    Pai MP; Jones AL
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4441-3. PubMed ID: 15504877
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multicenter comparative evaluation of six commercial systems and the national committee for clinical laboratory standards m27-a broth microdilution method for fluconazole susceptibility testing of Candida species.
    Morace G; Amato G; Bistoni F; Fadda G; Marone P; Montagna MT; Oliveri S; Polonelli L; Rigoli R; Mancuso I; La Face S; Masucci L; Romano L; Napoli C; Tatò D; Buscema MG; Belli CM; Piccirillo MM; Conti S; Covan S; Fanti F; Cavanna C; D'Alò F; Pitzurra L
    J Clin Microbiol; 2002 Aug; 40(8):2953-8. PubMed ID: 12149358
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [CHROMAgar Candida with fluconazole: comparison with microdilution techniques].
    Linares MJ; Charriel G; Solís F; Casal M
    Enferm Infecc Microbiol Clin; 2003 Nov; 21(9):493-7. PubMed ID: 14572382
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study.
    Espinel-Ingroff A; Barchiesi F; Cuenca-Estrella M; Fothergill A; Pfaller MA; Rinaldi M; Rodriguez-Tudela JL; Verweij PE
    J Clin Microbiol; 2005 Sep; 43(9):4535-40. PubMed ID: 16145103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.